• 基本信息
    导师姓名： 吴哲褒 学科代码： 100210
    性别： 男 学科名称： 外科学
    培养单位： 附属瑞金医院 三级学科 神外
    导师类型： 博士生导师 专业领域名称： 外科学 专业学位
    联系方式： 021-64370045-666091 专业领域代码： 105111
    邮编： 200025 邮箱地址： 617103822@qq.com
  • 研究方向 (点击浏览详细信息)
  • 社会任职
     
    中国垂体瘤协作组秘书
    中国脑垂体救助计划发起人
    中国神经科学协会神经肿瘤分会委员
    上海市医师协会神经外科分会第二届委员会委员
    浙江省医学会神经外科分会青年委员会副主任委员
    中华医学杂志和中华神经外科杂志特约审稿专家
    中华医学杂志英文版编委
    上海市医学会神经外科专科分会第十届委员会委员
  • 科研项目
    项目编号项目名称课题来源起止年月批准经费承担职责
    81972339KBTBD7介导的DRD2泛素化降解对泌乳素瘤药物治疗敏感性的调控机制研究国家自然科学基金面上项目 2020-01~2023-12 55万元  课题负责人
    81671371H19阻止ATG7泛素化降解增敏卡麦角林疗效的机制研究国家自然科学基金面上项目 2017-01~2020-12 52万元  课题负责人
    20161407侵袭海绵窦泌乳素腺瘤的撤药安全性研究上海交通大学医学院“双百人计划-研究型医师” 2016-07~2019-06 100万元  课题负责人
    81471392自噬在卡麦角林治疗中的作用及新机制探索国家自然科学基金面上项目 2015-01~2018-12 70万元  课题负责人
    2013T604185-HT受体在卡麦角林治疗溴隐亭耐药泌乳素腺瘤中的作用第六批中国博士后科学基金特别资助 2013-06~2013-11 15万元  课题负责人
    81271523lncRNA316686对NGFR的调控机制研究国家自然科学基金面上项目 2013-01~2016-12 70万元  课题负责人
    2012M520829lncRNA316686在泌乳素腺瘤药物治疗中的作用及机制研究中国博士后科学基金第52批面上资助 2012-06~2013-08 5万元  课题负责人
    R2091137吴哲褒研究团队浙江省自然科学基金杰出青年基金 2010-01~2013-12 30万元  课题负责人
    30800347腺病毒介导D2S基因和溴隐亭联合治疗垂体无功能腺瘤的实验研究国家自然科学基金青年基金项目 2009-01~2011-12 25万元  课题负责人
    2007C33028泌乳素腺瘤药物治疗的敏感性研究浙江省科技计划项目 2007-04~2009-12 17万元  课题负责人
  • 学术论文
    作者论文标题期刊名出版年卷期页码
    Liu YT, Liu F, Cao L, Xue L, Gu WT, Zheng YZ, Tang H, Wang Y, Yao H, Zhang Y, Xie WQ, Ren BH, Xiao ZH, Nie YJ, Hu R,  The KBTBD6/7-DRD2 axis regulates pituitary adenoma sensitivity to dopamine agonist treatment.  Acta Neuropathol  2020  doi: 10.1007/s00401-020-02180-4. 
    Lin S, Zhang A, Zhang X,  Treatment of Pituitary and Other Tumours with Cabergoline: New Mechanisms and Potential Broader Applications.  Neuroendocrinology  2020  doi: 10.1159/000504000 
    Zhang Y, Liu YT, Tang H, Xie WQ, Yao H, Gu WT, Zheng YZ, Shang HB, Wang Y, Wei YX, Wu ZR,  Exosome-transmitted lncRNA H19 inhibits the growth of pituitary adenoma.  J Clin Endocrinol Metab  2019  104(12):6345-6356 
    Zhong HP, Tang H, Zhang Y, Luo Y, Yao H, Cheng Y, Gu WT, Wei YX,  Multidisciplinary team efforts improve the surgical outcomes of sellar region lesions during pregnancy  Endocirne  2019  66:477-484 
    Yao H, Tang H, Zhang Y, Zhang QF, Liu XY, Liu YT, Gu WT, Zheng YZ, Shang HB, Wang Y, Huang JY, Wei YX, Zhang X, Zhang J,  DEPTOR inhibits cell proliferation and confers sensitivity to dopamine agonist in pituitary adenoma  Cancer Lett  2019  459:135-144. 
    Huang HY, Lin SJ, Zhao WG,  Cabergoline versus bromocriptine for the treatment of giant prolactinomas: A quantitative and systematic review.  Metab Brain Dis  2018  33(3):969-976 
    Huang HY, Zhai W, Tang H, Hui GZ,  Cabergoline for the treatment of bromocriptine-resistant invasive giant prolactinomas  Endocirne  2018  62(2):464-469 
    Wu ZR, Yan L, Liu YT, Cao L, Guo YH, Zhang Y, Yao H, Cai L, Shang HB, Rui WW, Yang G, Zhang XB, Tang H, Wang Y, Huang JY, Wei YX, Zhao WG, Su B,  Inhibition of mTORC1 by lncRNA H19 via disrupting 4E-BP1/Raptor interaction in pituitary tumours  Nat Commun  2018  9(1):4624 
    Xia MY, Lou XH, Lin SJ,  Optimal timing of dopamine agonist withdrawal in patients with hyperprolactinemia: a systematic review and meta-analysis.  Endocirne  2018  59(1):50-61 
    Leng ZG, Lin SJ, Wu ZR, Guo YH, Cai L, Shang HB, Tang H, Xue YJ, Lou MQ, Zhao W, Le WD, Zhao WG, Zhang X,  Activation of DRD5 (Dopamine Receptor D5) Inhibits Tumor Growth by Autophagic Cell Death  Autophagy  2017  14:1-16 
    Cai L, Leng ZG, Guo YH, Lin SJ, Wu ZR, Su ZP, Lu JL, Wei LF, Zhuge QC, Jin K,  Dopamine agonist resistance-related endocan promotes angiogenesis and cells viability of prolactinomas  Endocrine  2016  52(3):641-51 
    Wu ZR, Zhang Y, Cai L, Lin SJ, Su ZP, Wei YX, Shang HB, Yang WL, Zhao WG,  Long-Term Clinical Outcomes of Invasive Giant Prolactinomas after a Mean Ten-Year Followup  Int J Endocrinol  2016  2016:8580750 
    Lin SJ, Leng ZG, Guo YH, Cai L, Cai Y, Li N, Shang HB, Le WD, Zhao WG,  Suppression of mTOR pathway and induction of autophagy-dependent cell death by cabergoline  Oncotarget  2015  6(36):39329-41 
    , Cai L, Lin SJ, Leng ZG, Guo YH, Yang WL, Chu YW, Yang SH, Zhao WG  Heat shock protein 47 promotes glioma angiogenesis  Brain Pathol  2015  doi: 10.1111/bpa.12256 
    Cai L1, Leng ZG1, Guo YH1, Lin SJ2, Wu ZR1, Su ZP1, Lu JL1, Wei LF1, Zhuge QC1, Jin K3,,5.  Dopamine agonist resistance-related endocan promotes angiogenesis and cells viability of prolactinomas.  Endocrine  2015  DOI 10.1007/s12020-015-0824-2 
    ,Cai L, Qiu C,Zhang AL,Lin SJ,Yao Y,Xu J,Zhou LF  CTL responses to HSP47 associated with the prolonged survival of patients with glioblastomas  Neurology  2014  82:1261-1265 
    , Li WQ, Lin SJ, Wang CD, Cai L, Lu JL, Chen YX, Su ZP, Shang HB, Yang WL, Zhao WG  MicroRNA expression profile of bromocriptine-resistant prolactinomas.   Mol Cell Endocrinol.  2014  395:10-18 
    Huang L,, Zhuge Q, Zheng W, Shao B, Wang B, Sun F, Jin K  Glial scar formation occurs in the human brain after ischemic stroke  Int J Med Sci  2014  11(4):344-8 
    Qiang Li,Zhipeng Su,Jie Liu,Lin Cai,Jianglong Lu,Shaojian Lin,Zhengkun Xiong,Weiqiang Li,Weiming Zheng,Jinsen Wu,Qichuan Zhuge,  Dopamine receptor D2S gene transfer improves the sensitivity of GH3 rat pituitary adenoma cells to bromocriptine  Mol Cell Endocrinology  2014  382(1):377-384 
      应重视垂体催乳素腺瘤的药物治疗（述评）  中华医学杂志  2014  94(31):2404-2405. 
    , Chao Qiu, An Li Zhang, Lin Cai, Shao Jian Lin, Yu Yao, Qi Sheng Tang, Ming Xu, Wei Hua, Yi Wei Chu, Ying Mao, Jian Hong Zhu, Jianqing Xu, Liang Fu Zhou.  Glioma-associated antigen HEATR1 induces functional cytotoxic T lymphocytes in patients with glioma  Journal of Immunology Research  2014  131494:1-12 
    Lou XH*,, Zhang YZ  Bromocriptine-induced Brainstem Angulation in a Patient With Invasive Prolactinoma  J Clin Endocrinol Metab  2013  98(3):867-868 
    Yong Chen,Zhi Feng Li,Fei Xiang Zhang,Jian Xian Li,Lin Cai,Qi Chuan Zhuge,  Gamma knife surgery for patients with volumetric classification of nonfunctioning pituitary adenomas: a systematic review and meta-analysis  European J Endocrinology  2013  169(4):487-495 
    ,Lin Cai,Shao Jian Lin,Jiang Long Lu,Yu Yao,Liang Fu Zhou  The miR-92b functions as a potential oncogene by targeting on Smad3 in glioblastomas  Brain Research  2013  1529:16-25 
    ZhuGe Q*,, Huang L, Zhao B, Zhong M, Zheng W, Chen G, Mao X, Xie L, Wang X, Jin K  Notch4 is activated in endothelial and smooth muscle cells in human brain arteriovenous malformations  J Cell Mol Med  2013  17(11):1458-1464 
    ,Cai L,Lin SJ,Xiong ZK,Lu JL,Mao Y,Yao Y,Zhou LF  High-mobility group box 2 is associated with prognosis of glioblastoma by promoting cell viability, invasion, and chemotherapeutic resistance  Neuro-Oncology  2013  15(9):1264-1275 
    Yong Chen,Cheng De Wang,Zhi Peng Su,Yun Xiang Chen,Lin Cai,Qi Chuan Zhuge,  Natural History of Post-Operative Nonfunctioning Pituitary Adenomas: A Systematic Review and Meta-Analysis  Neuroendocrinology  2012  96(4):333-42 
    Su Z, Wang C, Wu J, Jiang X, Chen Y, Chen Y, Zheng W, Zhuge Q,, Zeng Y  Expression of dopamine 2 receptor subtype mRNA in clinically nonfunctioning pituitary adenomas  Neurol Sci  2012  33(2):275-279. 
    Zhipeng Su,Xiaolong Jiang,Chengde Wang,Jie Liu,Yunxiang Chen,Qun Li,Jinsen Wu,Weiming Zheng,Qichuan Zhuge,Kunlin Jin,  Differential effects of nerve growth factor on expression of dopamine 2 receptor subtypes in GH3 rat pituitary tumor cells  Endocrine  2012  42:470-475 
    CHENGDE WANG,ZHIPENG SU,NADER SANAI,XIANGYANG XUE,LIJUN LU,YUNXIANG CHEN,JINSEN WU,WEIMING ZHENG,QICHUAN ZHUGE,  microRNA expression profile and differentially-expressed genes in prolactinomas following bromocriptine treatment  Oncology Reports  2012  27:1312-1320 
      药物治疗垂体催乳素腺瘤的现状分析（述评）  中华神经外科杂志  2011  27(9):865-867 
    ,Wei Ming Zheng,Zhi Peng Su,Yong Chen,Jin Sen Wu,Cheng De Wang,Chen Lin,Yan Jun Zeng,Qi Chuan Zhuge  Expression of D2RmRNA isoforms and ERmRNA isoforms in prolactinomas: correlation with the response to bromocriptine and with tumor biological behavior  J Neuro-Oncology  2010  99(1):25-32 
    ,Chu Zhong Li,Xu Yi Zong,Zhi Peng Su,Yan Jun Zeng,Ya Zhuo Zhang  Correlation of alternative splicing of the D2 dopamine receptor mRNA and estrogen receptor mRNA in the prolactinomas and gonadotrope tumors  J Neuro-Oncology  2009  94:135-139 
    , Su ZP, Wu JS, Zheng WM, Zhuge QC, Zhong M  Five years follow-up of invasive prolactinomas with special reference to the control of cavernous sinus invasion  Pituitary  2008  11(1):63-70 
    , Yu CJ, Su ZP, Zhuge QC, Wu JS, Zheng WM  Bromocriptine treatment of invasive giant prolactinomas involving the cavernous sinus: Results of a long-term follow up  J Neurosurg  2006  104(1):54-61 
    , Yu CJ, Guan SS  Posterior petrous meningiomas: 82 cases.  J Neurosurg  2005  102(2):284-289